Oncotype DX: What Does the Score Mean?

If you’ve been diagnosed with early-stage, hormone receptor-positive, HER2-negative breast cancer, your doctor may order a test called Oncotype DX. This test helps estimate how likely your cancer is to come back and whether chemotherapy is likely to add meaningful benefit to your treatment plan.

What Is Oncotype DX?

Oncotype DX is a genomic test performed on breast cancer tissue after biopsy or surgery. It looks at the activity of 21 genes within the tumor and gives a score between 0 and 100, called a Recurrence Score.

The score helps your oncology team understand two important things:

• Your estimated risk of cancer recurrence
• Whether chemotherapy is likely to provide additional benefit beyond hormone therapy

What Does the Oncotype Score Mean?

In general, the lower the score, the less likely chemotherapy is to provide meaningful benefit. The higher the score, the more likely chemotherapy may be recommended.

General Score Ranges

• 0–25: Lower to intermediate recurrence score
• 26–100: Higher recurrence score

A score of 26 or higher is generally the point where chemotherapy is more strongly considered or recommended, especially in early-stage, hormone receptor-positive, HER2-negative breast cancer.

Does a Low Score Mean No Chemo?

Often, yes — but not always. For many women with node-negative, hormone receptor-positive, HER2-negative breast cancer, a score of 0–25 may mean chemotherapy can be avoided, especially in women over age 50.

However, age, menopausal status, lymph node involvement, tumor size, grade, and your overall health all matter. The Oncotype score is one tool your oncology team uses — not the only factor.

Why Age and Menopause Matter

One of the most confusing parts of Oncotype is that the same score may mean different things depending on whether someone is premenopausal or postmenopausal.

For many postmenopausal women with scores between 0 and 25, chemotherapy may not add meaningful benefit.

For some premenopausal women, especially those with higher scores in the intermediate range or lymph node involvement, chemotherapy may still be discussed because there may be benefit — although some of that benefit may come from ovarian suppression.

What If Lymph Nodes Are Positive?

Oncotype can also be used in some women with 1–3 positive lymph nodes, particularly when the cancer is hormone receptor-positive and HER2-negative.

In postmenopausal women with 1–3 positive nodes and an Oncotype score of 0–25, studies have shown that chemotherapy may not provide additional benefit.

In premenopausal women with positive nodes, chemotherapy may still be recommended or strongly discussed, even with a score of 0–25.

Questions to Ask Your Oncologist

• What is my Oncotype score?
• Am I considered premenopausal or postmenopausal?
• Were any lymph nodes involved?
• How much benefit would chemotherapy add for me specifically?
• Could ovarian suppression plus hormone therapy be an alternative to chemotherapy?
• How does my tumor grade, size, and overall pathology affect this decision?

The Bottom Line

Oncotype DX helps personalize breast cancer treatment. It can help some women safely avoid chemotherapy, while identifying others who are more likely to benefit from it.

The most important thing to remember is this: your score does not make the decision by itself. Your oncology team will interpret your score alongside your age, menopausal status, lymph node status, tumor biology, and personal preferences.

If you feel confused by your score, you are not alone. Ask your doctor to explain your absolute benefit from chemotherapy in plain language, so you can make the decision that feels most informed and aligned with your body, your values, and your treatment goals.

This article is for educational purposes only and should not replace medical advice from your oncology team.